Business Wire

City of Vienna Earns IEEE AI Ethics Certification Mark; Reinforcing Commitment to Digital Humanism Strategy

15.11.2021 18:30:00 EET | Business Wire | Press release

Share

IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE SA) today announced that the City of Vienna has become the first city worldwide to earn the IEEE CertifiAIEd AI Ethics (AIE) Certification Mark to advance the city’s Digital Humanism strategy.

"With artificial intelligence, we can make many tasks in administration more efficient and faster. As the City of Vienna, we are taking on a pioneering role here," says Peter Hanke, City Councillor for Economic Affairs. "Particularly in direct contact with people and especially in dealing with data, caution is required. People are at the center of our considerations."

The IEEE CertifAIEd mark recognizes that a product, service, or system has been verified to meet relevant ethical criteria, contributing towards a greater level of confidence and demonstrating a proactive approach to building public trust in AI systems. There are currently four sets of criteria available for IEEE CertifiAIEd certification:

  • Transparency criteria relate to values embedded in a system design, and the openness and disclosure of choices made for development and operation.
  • Accountability criteria recognize that the system/service autonomy and learning capacities are the results of algorithms and computational processes designed by humans and organizations that remain responsible for their outcomes.
  • Algorithmic bias criteria relate to the prevention of systematic errors and repeatable undesirable behaviors that create unfair outcomes.
  • Privacy criteria are aimed at respecting the private sphere of life and public identity of an individual, group, or community, upholding dignity.

“IEEE has laid the groundwork for AI Ethics based on principles and standards created by hundreds of our volunteers over the past five years, which are already having a global impact,” said Konstantinos Karachalios, Managing Director of IEEE SA. “IEEE CertifAIEd represents our continued evolution of the AI Ethics ecosystem by establishing a program to inspire trust and a means towards responsible implementation of AI systems that demonstrates an organization’s commitment to upholding human values, dignity, and well-being, and to respecting, protecting and preserving fundamental human rights. We are honored to work with the City of Vienna to support their Digital Humanism platform and to provide the mark for responsible innovation required in today’s world to inspire certified trust for their AI Systems.”

IEEE’s CertifAIEd program aims to enhance confidence in public and private enterprises that realize the benefits of AI ethics by earning certification in the absence of or as a complement to broadly accepted and enforced regulations for AI. As proposed legislation in the EU would require conformity certification for any AI based systems to mitigate any unintended risks, the City of Vienna is addressing these risks and demonstrating the benefits of responsible government innovation by earning the IEEE CertifAIEd mark. In doing so, it sets a precedent for other cities and entities to achieve their aims in a responsible and human-centric manner.

"Data security and data protection must be at the forefront when using AI from the very beginning. That's why we relied on international expertise during the development of the software and had our program ethically certified," said Deputy Director General, Peter Weinelt.

Cities, entities, and individuals interested in learning more about the criteria or getting involved in the program can visit the IEEE CertifAIEd website.

To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook, follow us on Twitter, connect with us on LinkedIn, or on the Beyond Standards Blog.

About the IEEE Standards Association

IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards, and industry solutions shaping a better, safer and sustainable world. For more information, visit https://standards.ieee.org.

About IEEE

IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tania Olabi-Colon, Director, Brand Marketing & Communications

Olivia Wang, Marketing & Communications Manager
standards-pr@ieee.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye